NewAmsterdam Pharma (NAMS) Cash & Equivalents (2021 - 2026)

NewAmsterdam Pharma has reported Cash & Equivalents for 6 years, with the latest figure at $457.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 38.86% year-over-year to $457.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $457.6 million (down 38.86% YoY) and the FY2025 annual result came in at $490.0 million, down 36.51% from the prior year.
• Cash & Equivalents retreated to $457.6 million in Q1 2026 per NAMS's latest filing, from $490.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $771.7 million in Q4 2024 and troughed at $340.4 million in Q4 2023.
• A 5-year average of $494.2 million and a median of $452.5 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents surged 636.64% in 2022, then tumbled 38.86% in 2026.
• Over 5 years, Cash & Equivalents stood at $447.4 million in 2022, then dropped by 23.9% to $340.4 million in 2023, then jumped by 126.68% to $771.7 million in 2024, then tumbled by 36.51% to $490.0 million in 2025, then decreased by 6.61% to $457.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $457.6 million, $490.0 million, and $538.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.